Abstract Details

Title Is Colchicine Effective for Preventing Ischemic Stroke? A Real-World Analysis

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 14-007

Objective

This study aims to analyze the effects of colchicine for secondary prevention of ischemic stroke and major adverse cardiovascular events (MACE) through data from a Global Federated Health Network.

Background Colchicine has been used for conditions like gout and familial Mediterranean fever. Its anti-inflammatory properties have made it a valuable therapeutic option in the management of autoimmune and inflammatory diseases. Recent studies suggest its potential benefits in cardiovascular conditions, including stable ischemic heart disease. However, its role in the secondary prevention of ischemic stroke and major cardiovascular events remains uncertain.

Design/Methods This observational study analyzed anonymized electronic medical records obtained from a global health research network, with a primary focus on healthcare organizations in the United States. The study evaluated the effects of colchicine on secondary prevention of ischemic stroke (ICD-10 I63) over a minimum treatment period of three months. Propensity score matching (PSM) was employed to balance baseline characteristics and reduce confounding factors, ensuring comparability between patients who received colchicine and those who did not. The analysis controlled for key variables, including diabetes mellitus, hypertensive diseases, overweight and obesity, and disorders of lipoprotein metabolism and other lipidemias.

Results 218,171 patients were identified, with 15,176 patients in each branch after PSM. The monitoring period lasted approximately 2.5 years, with a standard deviation of about 2.8 years. Contrary to recent studies, the risk ratio of secondary events was higher in the colchicine group compared to the control group (RR 1.082, 95% CI 1.051 - 1.114). There was no significant difference in the mortality rate between the groups (HR 0.976, 95% CI 0.937 - 1.015).

Conclusions

In this real-world study, colchicine showed a reduced risk of secondary events in patients with a history of stroke or coronary artery disease. These findings emphasize the necessity for additional clinical trials to verify these outcomes and examine the underlying mechanisms involved.

Authors/Disclosures
Matheus D. Pereira, MD PRESENTER	Dr. Pereira has nothing to disclose.
Henrique Cian da Cruz	Mr. Cian da Cruz has nothing to disclose.
Mariana Letícia d. Maximiano, MD	Dr. Maximiano has nothing to disclose.
Savio Batista, MD (Emory University)	Mr. Batista has nothing to disclose.
Julia Tirelli Rocha, MD	Dr. Tirelli Rocha has nothing to disclose.

��ɫ��

��ɫ��